Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers |
| |
Authors: | Kudoh Kazuya Takano Masashi Kouta Hiroko Kikuchi Ryoko Kita Tsunekazu Miyamoto Morikazu Watanabe Akio Kato Masafumi Goto Tomoko Kikuchi Yoshihiro |
| |
Affiliation: | a Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama, Japanb Department of Obstetrics and Gynecology, Nishisaitama-Chuo National Hospital, Tokorozawa, Saitama, Japanc Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japand Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japane Department of Obstetrics and Gynecology, Nara Prefectural Nara Hospital, Nara, Nara, Japan |
| |
Abstract: | ObjectivesCurrently, pegylated liposomal doxorubicin (PLD) is regarded as one of the standard treatment options in recurrent ovarian cancers (ROC). Bevacizumab has shown significant antitumor activity for ROC in single-agent or in combination with cytotoxic agents. We have conducted a preliminary study to investigate effects of combination of bevacizumab and PLD for heavily pretreated patients with ROC.MethodsThirty patients with ROC were treated with combination therapy with weekly bevacizumab and PLD, 2 mg/kg of continuous weekly bevacizumab and 10 mg/m2 of PLD (3 weeks on, 1 week off). The treatment was continued until development of disease progression, or unmanageable adverse effects. Response evaluation was based upon Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, and Gynecologic Cancer Intergroup (GCIG) CA125 response criteria. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.ResultsOverall response rate was 33%, and clinical benefit rate (CR + PD + SD) was 73%. Median progression-free survival was 6 months (range: 2-20 months), and a 6-months progression-free survival was 47%. Any hematological toxicities more than grade 3 were not observed. Two cases developed non-hematologic toxicities more than grade 2; a case with grade 3 hand-foot syndrome, another with grade 3 gastrointestinal perforation (GIP). The case with GIP was conservatively treated and recovered after 2 months, and there was no case with treatment-related death.ConclusionThe present investigation suggested that combination therapy with bevacizumab and PLD was active and well tolerated for patients with ROC. We recommend the regimen be evaluated in further clinical studies. |
| |
Keywords: | Ovarian cancer Refractory Recurrent Bevacizumab Pegylated liposomal doxorubicin |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|